5537 Background: The epidermal growth factor receptor (EGFR) is expressed in nearly all
SCCHN and carries a strong prognostic significance, providing the rationale for using EGFR …

5513 Background: The goal of this study was to investigate the safety and efficacy of
cetuximab (Erbitux), an IgG1 monoclonal antibody targeting the EGFR, given in combination …

Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
(SCCHN) have a poor prognosis, particularly those whose disease has progressed on …

BACKGROUND. The epidermal growth factor receptor (EGFR) inhibitor cetuximab is active
in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The …

Background Cetuximab plus platinum‐based therapy (PBT) followed by cetuximab
maintenance until progression (EXTREME) is a guideline‐recommended first‐line treatment …

Purpose This was an open, randomized, multicenter, phase I/II study to investigate the safety
and tolerability of cetuximab in the first-line treatment of recurrent/metastatic squamous cell …

5505 Background: Patients with R&M SCCHN have a poor prognosis. Patients failing first-
line therapy have few therapeutic options. Cetuximab (Erbitux) is an IgG1 monoclonal …

Abstract Background B490 (EudraCT# 2011-002564-24) is a randomized, phase 2b,
noninferiority study investigating the efficacy and safety of first-line cetuximab plus cisplatin …

Purpose To evaluate the efficacy and safety of the epidermal growth factor receptor–directed
monoclonal antibody cetuximab administered as a single agent in patients with recurrent …

Background The use of cetuximab in combination with platinum (P) plus 5-fluorouracil (F)
has previously been demonstrated to be effective in the treatment of metastatic squamous …